What question did this study set out to answer?

April 17, 2026Open Access

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma

Puntos clave

The aim is to validate the very favorable IMDC risk group in metastatic renal cell carcinoma and assess treatment outcomes.
Conducted a cohort study
Compared outcomes of very favorable risk subgroup and favorable risk group
Analyzed survival rates with different treatment regimens such as VEGF-TT and IO-VE
Very favorable risk subgroup displayed superior outcomes with VEGF-containing regimens
IO-IO combination resulted in significantly worse survival
Suggests that VEGF inhibition is vital for achieving optimal outcomes

Resumen

In this cohort study, the very favorable risk subgroup had a less immunogenic molecular profile and superior outcomes from VEGF-containing regimens (VEGF-TT and IO-VE) compared with the favorable risk group. The IO-IO combination showed significantly worse survival in this population, suggesting that VEGF inhibition remains essential for optimal outcomes.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo